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a  b  s  t  r  a  c  t
Objective:  To  establish  the  prevalence  of Trypanosoma  cruzi  infection  in  Bolivian  (Spain)  participants.
Methods:  A  cross  sectional  study  was carried  out  in  Majorca.  Bolivian  residents  older  than  18 years
assigned  to the  family  physicians  of two  primary  care  centers  were  randomly  selected  from  the  health
card  population  database.  Participants  were  invited  to attend  a serology  test  and  an  interview.  T. cruzi
infection  was  conﬁrmed  after  two  positive  ELISA  tests.  If the  result  was positive  or  dubious,  the  serological
test  was  sent  to  the National  Microbiology  Center  for  conﬁrmation.
Results:  A  total  of  251  participants  were  included  (response  rate  36.3%).  The  overall  seroprevalence  of
Chagas  infection  was  19.1%  (95%  CI: 14.06-24.19).  Seroprevalence  was  higher  in  participants  from  highly
endemic  provinces,  those  from  rural  areas,  those  who  had  lived  in mud  houses,  and  in those  whose
mother  or  a family  member  had  contracted  this  infection.
Conclusion:  This  study  demonstrates  a high  prevalence  of T. cruzi  in Bolivian  residents,  which  was  strongly
associated  with established  risk  factors.
©  2014  SESPAS.  Published  by  Elsevier  España,  S.L.U.  All  rights  reserved.
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Objetivo:  Este  estudio  pretende  estimar  la seroprevalencia  de  la  infección  por Tripanosoma  cruzi  en sujetos
bolivianos.
Métodos:  Estudio  descriptivo  transversal  en  Mallorca  (Espan˜a),  en  el  cual  sujetos  bolivianos  mayores  de
18 an˜os,  asignados  a médicos  de  familia  de  dos  centros  de  salud,  fueron  seleccionados  aleatoriamente  de
la base  de  Tarjeta  Sanitaria  Individual.  Se  citaron  en  el  centro  de  salud  para  prueba  serológica  y  entrevista.
Se  conﬁrma  como  caso  dos pruebas  de  ELISA  positivas.  Los  resultados  positivos  o dudosos  se enviaron  al
Centro  Nacional  de  Microbiología  para  su conﬁrmación.
Resultados:  Se incluyeron  251  sujetos  (tasa de  respuesta  36,3%).  La seroprevalencia  fue del 19,1%  (inter-
valo de  conﬁanza  del  95%:  14,06-24,19).  La  seroprevalencia  fue  mayor  en  quienes  vivían en provincias
endémicas,  áreas  rurales,  casas  de  adobe  o cuya  madre  o  algún  familiar  había  sufrido  la infección.
Conclusión:  Este  trabajo  evidencia  una  alta  prevalencia  en  personas  bolivianas  residentes  que se asocia
con  los factores  de riesgo  ya  establecidos
© 2014  SESPAS.  Publicado  por  Elsevier  España,  S.L.U.  Todos  los derechos  reservados.ntroductionChagas disease is one of the seventeen called neglected tropi-
al diseases, as well as the parasitosis with the highest morbidity
nd socioeconomic impact in the American continent.1 It is caused
∗ Corresponding author.
E-mail addresses: janaribases@yahoo.es, jribas@hsll.es (J. Ribas).
http://dx.doi.org/10.1016/j.gaceta.2015.03.012
213-9111/© 2014 SESPAS. Published by Elsevier España, S.L.U. All rights reserved.by a ﬂagellate protozoan, Trypanosoma cruzi, transmitted by the
bite of an haematophagus insect.2 Approximately 70% of infected
patients will continue asymptomatic and the rest will develop
symptoms.
Since the 80s, and due to the important migratory movements
from endemic areas, it was  predicted that in a near future Cha-
gas disease would become a public health issue in non-endemic
countries. The lack of identiﬁcation and treatment increases the
risk of health complications and transmission.3
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Spain is estimated to be, after USA, the country with the high-
st number of immigrants from Latin America,3 as well as one of
he non-endemic countries with the highest prevalence of Chagas
isease.4 In 2012 there were 1,633,755 Latin American immigrants
n our country, from those, a 12.18% came from Bolivia,5 where an
0% of the country is endemic. The Balearic Islands present the same
gures, with 59,126 Latin American immigrants, of which 10.81%
ere born in Bolivia5. Most of these people will be attended in
rimary care at sometime therefore, it is necessary to provide esti-
ates of the presence of Chagas infection in primary care Bolivian
opulation. This study aims to estimate the prevalence of Chagas
isease in Bolivian subjects living in Majorca (Spain).
aterial and methods
We  carried out a descriptive study (October 2011-March 2012)
n Palma health centers of Escuela Graduada (22,060 inhabitants)
nd Son Pisà (23,000 inhabitants) with a percentage of non UE
mmigrant population of around 12%. At the beginning of the study,
,731 Bolivians were registered with a general practitioner (GP) in
ajorca, of those 7,646 lived in Palma city and 1,609 (18.43%) were
egistered in the study health centers.
Subjects included were those born in Bolivia, 18 years and
lder. Subjects were excluded if they had a great disability, had no
able 1
istribution of Bolivian study subjects according to sociodemographic characteristics and
011-March 2012.
Variables Total
N (%)
S
N
Sex
Men 145 (57.8) 2
Women  106 (42.2) 2
Mean  age (SD) 34.62 (9.3) 3
Province of origin
La Paz 47 (19.0) 
Santa Cruz 56 (22.6) 1
Cochabamba 111 (44.8) 2
Chupisaca-Potosi-Tarija 22 (8.9) 1
Other provinces less risk 12 (4.8) 
Time  since leaving Bolivia
<4 years 24 (9.6) 
≥4  years 227 (90.4) 4
Area
Rural  126 (50.2) 3
Urban 125 (49.8) 1
House
Mud  147 (58.8) 3
Brick 103 (41.2) 1
Mother serology
Positive 14 (7.4) 
Negative 176 (92.6) 2
Chagas in relatives
Yes 67 (30.2) 2
No  155 (69.8) 1
Have  seen the insect
Yes 168 (67.7) 4
No  80 (32.3) 
Experience of transfusion
Yes 30 (12.0) 
No  221 (88.0) 4
Previous Chagas results
Positive 39 (15.5) 
Negative 212 (84.5) 2
Previous Chagas treatment
Yes 4 (1.7) 
No  236 (98.3) 4
D: standard deviation.it. 2015;29(4):288–291 289
telephone or rejected to participate. We  estimated a sample size of
264 subjects for a 7% prevalence,6 a precision of 3% and 95% conﬁ-
dence level. Considering possible low response rate, we decided to
contact 691 subjects.
Subjects were selected through computer systematic random
sampling from the list of Bolivians registered in the Health Card
population data base of the two health centers (where most of the
authors were working). Individuals were invited to participate by
telephone and given an appointment. After signing an informed
consent, an interview and a blood extraction were carried out.
The serological sample was  sent to the microbiology laboratory
at Son Espases Hospital. A ﬁrst immunochromatographic sero-
logical diagnostic method was  performed (SD Chagas Ab Rapid
Bioline Standard Diagnostics, Inc) with 90.4% sensitivity and 94%
speciﬁcity.7 A negative test was considered negative for Chagas
disease. If the result was  positive or doubtful, the sample was  sent
to the National Microbiology Center laboratory for its conﬁrma-
tion through a second different ELISA (“IFI in house”) with 98.5%
sensitivity and 100% speciﬁcity.8
Data were collected on age and sex; T. cruzi risk factors, knowl-
edge about the disease and results of the serology.
The chi-squared test was  used to assess the relationship
between the prevalence of T. cruzi infection and categorical vari-
ables and Student’s t test for age. A backward conditional logistic
 Chagas infection risk factors in two health care centers in Palma (Majorca), October
erology +
 (%)
Serology - N (%) p
2 (15.2) 123 (84.8)
6 (54.2) 80 (24.5) 0.06
5.5 (10.2) 34.4 (9.1) 0.58
3 (6.4) 44 (93.6)
1 (19.6) 45 (80.4)
2 (19.8) 89 (80.2)
5 (68.2) 7 (31.8)
1 (8.3) 11 (91.7) 0.08
5 (20.8) 19 (79.2)
3 (18.9) 184 (81.1) 0.82
3 (26.2) 93 (73.8)
5 (12.0) 110 (88.0) 0.004
6 (24.5) 111 (75.5)
2 (11.7) 91 (88.3) 0.01
8 (57.1) 6 (42.9)
4 (76.5) 150 (57.1) <0.001
0 (29.9) 47 (70.1)
7 (11.0) 138 (89.0) 0.001
2 (25.0) 126 (75.0)
5 (6.2) 75 (93.8) <0.001
6 (20.0) 24 (80.0)
2 (19.0) 179 (81.0) 0.89
5 (71.4) 2 (28.6)
1 (19.6) 86 (80.4) 0.002
3 (75.0) 1 (25.0)
5 (19.1) 192 (80.9) 0.006
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Table 2
Distribution of knowledge variables about Chagas disease among Bolivian immigrants from two health care centers in Palma (Majorca) October 2011-March 2012.
Variables Total Serology + N (%) Serology - N (%) p
The disease is produced by an insect bite
Yes 196 (91.6) 42 (95.5) 154 (90.6) 0.30
No  18 (8.4) 2 (4.5) 16 (9.4)
The  disease is not very frequent in Spain
Yes 159 (84.1) 34 (89.5) 125 (82.8) 0.31
No  30 (15.9) 4 (10.5) 26 (17.2)
It  is spread by transfusion
Yes 164 (87.7) 36 (94.7) 128 (85.9) 0.13
No  23 (12.3) 2 (5.3) 21 (14.1)
It  is spread by pregnancy
Yes 163 (87.6) 29 (78.4) 134 (89.9) 0.056
No  23 (12.4) 8 (21.6) 15 (10.1)
It  is spread by organ donation
Yes 64 (37.6) 16 (48.6) 48 (35.0) 0.15
No  106 (62.4) 17 (51.5) 89 (65.0)
It  is spread through skin
Yes 40 (20.1) 7 (19.4) 33 (20.2) 0.91
No  159 (79.9) 33 (80.6) 130 (79.8)
It  is spread through sexual contact
Yes 83 (48.8) 11 (40.7) 72 (50.3) 0.36
No  87 (51.2) 16 (59.3) 71 (49.7)
An  infected subject can be asymptomatic
Yes 140 (71.8) 26 (70.3) 114 (72.2) 0.81
No  55 (28.2) 11 (29.7) 44 (27.8)
Chagas can affect the heart
Yes 182 (94.8) 37 (92.5) 145 (95.4) 0.46
No  10 (5.2) 3 (7.5) 7 (4.6)
Chagas can affect the esophagus
Yes 104 (78.8) 19 (73.3) 85 (80.2) 0.42
No  28 (21.2) 7 (26.9) 21 (19.8)
Chagas can affect the intestine
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No  32 (23.4) 
egression analysis was performed to evaluate the independent
ffect of risk factors over the prevalence. All signiﬁcant variables
n the bivariate analysis were included. Reception of any Chagas
reatment was excluded because colinearity with previous Cha-
as results was detected. The study received the approval of the
ajorca Primary Care Research Committee.
esults
We  included 251 subjects of the initial sample (691). Reasons
or not participation were: 281 did not answer to 3 phone calls,
2 rejected participation, 24 changed address, 57 wrong telephone
umber, 19 previous serology and 27 <18 years old.
Epidemiological data are presented in Table 1. Forty eight were
ositive, which means a prevalence of 19.1% (CI95%: 14.06-24.19),
o false positive cases were detected. A total of 75% of men  and
0% of women were between 18- 39 years old. Most of the studied
isk factors were signiﬁcantly related with the presence of Cha-
as disease. Subjects coming from Cochabamba, Santa Cruz and
hupisaca regions presented signiﬁcantly higher prevalence that
hose from other regions, as well as subjects reporting having lived
n rural areas, mud  houses or those referring a history of infec-
ion for their mother or relatives. No signiﬁcant differences were
ound for age, sex, years out of Bolivia or transfusion experience.
ive subjects declared not having seen the insect but all had more
han one risk factor. In the adjusted model, predictive factors for
nfection were: women 2.09 (95%CI: 0.9-4.59), reported familiar66.7) 85 (79.4) 0.14
33.3) 22 (20.6)
infection 2.65 (95%CI: 1.19-5.76) and having seen the insect 4.79
(95%CI: 1.37-16.70).
A total of 35 (14.5%) subjects declared being blood donors, 5
of them (14.3%) resulted in positive serology. Furthermore, 5 (2%)
subjects declared being organ donors; 2 of them (40%) with positive
results for T. cruzi.
As shown in Table 2, there is an important level of information
about the disease. There were no statistically signiﬁcant differences
on the knowledge level according to serological results.
Discussion
Our study shows that 19.1% of the Bolivian immigrants living
in Majorca are infected with T. cruzi, and that a high percentage
present risk factors associated with Chagas disease. This study uses
a community-based approach in order to provide a fair estimate of
Chagas prevalence. The practical difﬁculties associated with ran-
dom sampling from a community sample frame resulted in a less
optimal estimate of the disease presence in this population.
This high prevalence matches the results found in other Spanish
studies9,10. For instance, Roca et al. found a prevalence of 16.53%
among Bolivians compared with a 2.87% in the total Latin Ameri-
can studied population.9 In Switzerland prevalence among Bolivian
population was  of 26.6%, whereas the global one was of 12%.11Some authors point out that the heterogeneity in prevalence
estimation varies according to the studied immigrant origin and the
recruiting scenario. Thus, patients recruited in primary care would
present lower prevalence than that found in reference centers12,13.
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Our results are also similar to those of other studies, when
eferring to the relationship of risk factors and positive serology.
isk factors not associated with positive serology prevalence in the
tudy, were time out of Bolivia and origin region, probably because
ost subjects came from high incidence regions. Our sample was
ery similar to the one of Jackson et al,11 regarding age but in
ontrast, we did not ﬁnd differences by age. We  did ﬁnd higher
revalence in women compared with other studies9,11.
The persons interviewed have a high knowledge level about
hagas disease. Few studies have explored this subject among Latin
merican population.9 These results could be due to the Bolivian
rograms that aim sensitizing and informing the population.
Despite the high estimated prevalence of Chagas disease
bserved, it is difﬁcult to conclude that Bolivian subjects living in
ur country, could globally proﬁt from population screening of the
isease, as no beneﬁts of this procedure have been reported to date.
 detailed assessment of the cost-beneﬁt of implementing a pop-
lation screening should be carried out, even when there is not
et an absolute indication about the need of treating all patients
n the chronic indeterminate phase.14 In Spain, T. cruzi screening
s highly established in blood or high risk organ donors. However,
rotocol performance in pregnant and childbearing age women,
nd newborns is more optional. Thus, a national consensus to apply
rotocols in these women is necessary.15
The strongest point in our study refers to the random subject
election from the Health Card population data base of two  health
enters. This could lead to a prevalence estimate of Chagas disease
n a non selected Bolivian population as compared with health care
ttendees or refugees. However, there could be a biased estimation
f prevalence if Bolivian population registered in other health cen-
ers or non participation are related with T. cruzi risk factors, such
s origin region.
In conclusion, a high prevalence of Chagas disease in the Bolivian
opulation has been observed, especially in those that presented
he common risk factors. Due to the high T. cruzi infection frequency
n population from Bolivian origin compared with those coming
rom other Latin American countries, the screening in this group
hould be considered to avoid the transmission and progression of
he disease.
What is known about the topic?
Spain is estimated to be one of the non-endemic countries
with the highest prevalence of Chagas disease, and the Euro-
pean country with the highest number of cases. Studies
to learn the real magnitude of the disease in non-endemic
countries are required, as most of the reviewed works are not
population based.
What does this study add to the literature?
This population based study shows that 19.1% of the
Bolivian immigrants living in Mallorca are infected with Try-
panosoma cruzi, and that a higher percentage present risk
factors associated with Chagas disease. We  believe that there
is a need to involve primary and hospital care professionals in
the awareness, monitoring and management of a disease that
is still cornered to the drawer of ignorance.ditor in charge
Pere Godoy.
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